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direct costs of the medications were ascertained from the
latest monthly index for medical specialities (MIMS), and
from standard chemists, and pharmaceutical firms. The
statistical mode or most frequent cost was considered for
further computations.
RESULTS: Regarding antidepressants, tricyclics were noted
to have the following annual direct costs (1 US $  Rs. 43):
Imipramine Rs. 1130 (US$26.3), amitriptyline Rs. 1460
($34), dothiepin Rs. 2410 ($56.1), trimipramine Rs. 2430
($56.5) and clomipramine Rs. 6130 ($142.6). Fluoxetine
has an annual cost of Rs. 840 ($19.5), mianserin Rs. 2010
($46.7), amoxapine Rs. 3835 ($89.1), amineptine Rs.
10,700 ($248.8), and the most expensive, tianeptine Rs.
21,000 ($488). The recently introduced antidepressant ser-
traline has an annual cost of Rs. 2740 ($63.7). Prophylaxis
for affective disorders with lithium therapy would have an
annual cost of Rs. 1200 ($27.9). Regarding antipsychotics
the annual direct costs of oral medications of chlorprom-
azine and haloperidol were same, Rs. 2000 ($46.5), long
acting oral penfluridol Rs. 500 ($11.6), and depot long act-
ing injectable fluphenazine decanoate, haloperidol de-
canoate, and flupenthixol Rs. 750 ($17.4), Rs. 1500 ($34.9)
and Rs. 2100 ($48.8), respectively. Newer atypical antipsy-
chotics risperidone, Rs. 4500 ($104.7) and clozapine Rs.
5500 ($127.9). Benzodiazepines have an annual cost of
$7.5 for diazepam, $3.5 for lorazepam and chlordiazep-
oxide, $2.8 for oxazepam, and $17.6 for alprazolam. Sleep
medications nitrazepam, flurazepam, and zopiclone have an
annual cost of $3.3, $8, and $18.8, respectively.
CONCLUSION: The annual direct costs are compara-
tively less than those in Western nations, but nevertheless
these produce a significant burden on the Indian families,
and are a common reason for poor compliance. Another
trend that can be noted above is that newer antidepres-
sants like amineptine and tianeptine, antipsychotics like
risperidone and clozapine, and hypnotics like zopiclone
are much more expensive than the older medications.
Thus, the annual direct costs of medications are only
likely to increase with time, enhancing the financial bur-
den in the treatment of the psychiatric disorders.
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OBJECTIVES: To profile utilization of antipsychotic
medications at baseline in a prospective study of the out-
comes of treatment for schizophrenia in large systems of
care, and to evaluate characteristics associated with the
receipt of antipsychotic medication and the type of medi-
cation prescribed.
METHODS: Data are obtained from the Schizophrenia
Care and Assessment Program, a prospective study of the
course and outcomes of treatment for schizophrenia in six
large systems of care in the United States. The analysis
sample consists of approximately 1100 patients. Antipsy-
chotic medication use at baseline in this sample is profiled.
The effect of patient characteristics and prior period (pre-
vious 6 months) service utilization and medication history
on receipt of antipsychotic medication therapy at baseline
and the type of medication prescribed is modeled using lo-
gistic regression.
RESULTS: The presentation will profile antipsychotic
utilization at baseline in this sample of patients receiving
care in large service systems, and characterize the distri-
bution of use of conventional, new generation, and depot
medication. Regression analysis will evaluate factors as-
sociated with the receipt of antipsychotic medication
therapy and type of medication prescribed. Predictors
will include: patient demographic status (age, gender,
race/ethnicity, education, marital status, income, health
insurance status), diagnosis (type of schizophrenia), psy-
chiatric history, and pre-period health services utilization
and medication history.
CONCLUSIONS: The introduction of new pharmaco-
logic treatments for schizophrenia and the development of
evidence-based standards of care has accelerated the need
for information on patterns of medication therapy and
outcomes in usual care settings. This presentation will
profile antipsychotic medication use and factors associ-
ated with current prescribing practices in a large sample
of patients with schizophrenia who receive care in large
service systems.
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With the growing elderly population, the number of
older patients with mental and behavioral disorders has
increased. Psychotropic drugs are an integral part of
treatment for these conditions.
OBJECTIVE: This study describes the psychotropic agent
prescribing for the elderly in clinic settings during 1996.
METHODS: Data were abstracted from the 1996 Na-
tional Ambulatory Medical Care Survey and the Na-
tional Hospital Ambulatory Medical Care Survey. All
visits of patients 65 years of age or older involving psy-
chotropic drugs were selected from the national surveys.
National visit estimates and visit rates were derived based
on the patient sampling weight to describe psychotropic
prescribing for the elderly in ambulatory clinics.
RESULTS: Psychotropic medications were prescribed in
an estimated 16.55 million ambulatory clinic visits for
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the elderly in 1996. This represents 8.7% of all clinic vis-
its by the elderly for an annual visit rate of 51.97 (visits
for every 100 persons of 65 years old or older). Ninety-
one percent of these visits were to physician offices and
remaining visits were to outpatient clinics. There were
some variations in psychotropic prescribing patterns be-
tween these two settings. Overall, psychotropic medica-
tion visit rates were greater in females, blacks, patients
between 80 and 84 years of age, and patients from the
West. The most frequently prescribed psychotropic medi-
cations in ambulatory clinics in the order of prevalence
were antidepressants, antianxiety agents, and sedatives.
Most of the visits (81.67%) involved one psychotropic
medication and 3.14% of the visits involved two or more
agents in the same class.
CONCLUSION: The study revealed that psychotropic
prescribing practices in ambulatory clinics vary with eld-
erly demographics and clinical settings. Because of the in-
creased risk related to the use of psychotropics and the
prescribing patterns of these agents, future efforts may be
focused on populations receiving relatively more psycho-
tropic agents to improve healthcare outcomes.
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Burden-of-illness assessments require incidence and prev-
alence assumptions. For psychotic disorders, there are
few large-scale incidence and prevalence assessments pro-
viding rates for age, gender, or socioeconomic subpopu-
lations. Because outpatient treatment of psychotic condi-
tions is increasing, overall incidence and prevalence may
be estimated from outpatient pharmaceutical records.
OBJECTIVE: This study estimates incidence and prevalence
of antipsychotic utilization among age, gender, and payer
combinations using outpatient pharmaceutical records.
METHODS: Antipsychotic prescriptions dispensed be-
tween July 1995 and June 1997 to 4,628,528 eligible
subjects were extracted from a large US database. Calcu-
lated ratios compared utilizers (eligible subjects with a
prescription between July 1996 and June 1997) and initi-
ators (utilizers without a prescription between July 1995
and June 1996) to eligible subjects for various combina-
tions of age, gender, and payer types—Medicaid, non-
Medicaid, indemnity, or “self-insured.” Chi-square tests
were used to assess differences between those receiving
and not receiving antipsychotic agents.
RESULTS: The utilizer ratio was 5.0 per 1000, although
significantly (p  0.002) lower (by 1.1 per 1000) for
males. The initiator ratio was 1.6 per 1000, again signifi-
cantly (p  0.001) lower (by 0.1 per 1000) for males.
Differences were not consistent—higher for younger
males and lower for older males than for similarly aged
females. Ratios were significantly (p 	 0.001) higher (by
10 times) for Medicaid recipients.
CONCLUSION: Outpatient ratios were within overall
prevalence and incidence rates for schizophrenia or other
psychotic conditions. Integrating these ratios into a bur-
den-of-illness analysis should consider the proportions of
non-psychotic disorders, patients treated for psychotic
conditions without medication, and patients treated solely
on an inpatient basis.
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Heroin is an extremely devastating drug. Injection of her-
oin is a major risk factor for infectious diseases such as
HIV/AIDS and hepatitis. Heroin addiction often strikes
persons in the prime of their working years, robbing soci-
ety of productive citizens. Furthermore, a significant pro-
portion of heroin users engages in criminal activities to
support their habit.
OBJECTIVE: This study documents the tremendous
costs of heroin addiction, both to the addict and society
at large.
METHODS: Using a cost-of-illness approach, we identify
costs in three major areas: 1) medical care, 2) productivity,
and 3) crime. No single data set currently available is able
to fully capture costs in each of these areas. Thus, a variety
of data sets and previous studies have been synthesized.
RESULTS: We estimate that in 1996 the economic costs
of heroin addiction in the United States totaled $22.1 bil-
lion. Approximately 23% of these costs are due to the
medical complications of heroin addiction, primarily
treatment for HIV/AIDS and psychiatric comorbidities.
Another 24% are related to criminal activities, including
the cost of incarceration, policing, legal adjudication, and
the cost to crime victims. Another 41% are associated
with lost productivity. For example, heroin addicts are
less than half as likely to have a full-time job as com-
pared with the national average. Treatment of heroin ad-
diction and social welfare services each account for 5%
of the costs.
CONCLUSIONS: The significant economic effects of
heroin addiction have important public policy implica-
tions, especially given that heroin use appears to be rising
among adolescents and young adults. This study suggests
that greater investment in prevention and treatment ac-
tivities may be highly cost-effective.
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